KOL Insight - Hidradenitis Suppurativa

This report delves into the evolving landscape of hidradenitis suppurativa (HS) treatment, providing a comprehensive analysis of current and emerging therapies. Based on insights from interviews with 12 KOLs, it explores the pivotal role of TNF inhibitors like Humira amidst the rise of biosimilars, the promising potential of IL-17 inhibitors, such as UCB's Bimzelx, and the challenges and opportunities presented by oral JAK inhibitors, including Incyte's povorcitinib, and their place in the treatment algorithm.

This analysis is crucial for pharmaceutical professionals aiming to navigate the evolving therapeutic landscape and anticipate future developments in HS management.

Key Questions Answered:

• How are TNF inhibitors like Humira and Remicade currently utilized in hidradenitis suppurativa treatment, and what changes are anticipated with newer therapies?
• What impact is the rollout of anti-TNF biosimilars having on prescribing behavior, access, and pricing dynamics in the HS market?
• What is the real-world uptake of Novartis' IL-17A inhibitor Cosentyx, and how do experts expect its role to evolve?
• How do the latest clinical data for UCB's Bimzelx compare with Cosentyx, and what is its expected impact on the HS treatment landscape?
• What is the potential role of MoonLake Immunotherapeutics' sonelokimab in the IL-17 treatment landscape for HS?
• How do Incyte's JAK1 inhibitor povorcitinib and AbbVie's Rinvoq compare, and how might they be sequenced or combined in future practice?
• Where does the topical JAK inhibitor Opzelura fit into the HS treatment algorithm?
• What are the therapeutic potentials of alternative targets like IL-1-alpha-beta inhibition and BTK inhibition in HS treatment?
• What efficacy, durability, and safety benchmarks must pipeline products achieve to compete with established TNF and IL-17 inhibitors?
• What key unmet needs persist in HS, and are any late-stage agents poised to address these gaps?

Key Brands:

Partial List of Participating Experts:

• Professor and Director of the Departmental Division for Dermatology, Department of Medicine at the University of Toronto and Division Head of Dermatology at Women's College Hospital, Toronto
• Associate Professor of Internal Medicine & Dermatology at the University of Minnesota, MN
• Professor of Dermatology, Pathology and Public Health Sciences at the Wake Forest University School of Medicine, Winston-Salem, NC
• Professor in Experimental Immunodermatology, Erasmus MC, Rotterdam, Netherlands
• Clinical Professor, Department of Biomedical Sciences, University of Copenhagen, Denmark
• Head Physician, Dermatologist, Nordlandssykehuset Bodo, Professor of Skin and Venereal Diseases, The Arctic University of Norway, Norway

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.